Literature DB >> 22551565

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks.

Benjamin W Turney1, Martin Kerr, Meenali M Chitnis, Kunal Lodhia, Yong Wang, Johann Riedemann, Mark Rochester, Andrew S Protheroe, Simon F Brewster, Valentine M Macaulay.   

Abstract

BACKGROUND AND
PURPOSE: IGF-1R depletion sensitizes prostate cancer cells to ionizing radiation and DNA-damaging cytotoxic drugs. This study investigated the hypothesis that IGF-1R regulates DNA double strand break (DSB) repair.
METHODS: We tested effects of IGF-1R siRNA transfection on the repair of radiation-induced DSBs by immunoblotting and immunofluorescence for γH2AX, and pulsed-field gel electrophoresis. Homologous recombination (HR) was quantified by reporter assays, and cell cycle distribution by flow cytometry.
RESULTS: We confirmed that IGF-1R depletion sensitized DU145 and PC3 prostate cancer cells to ionizing radiation. DU145 control transfectants resolved radiation-induced DSBs within 24 h, while IGF-1R depleted cells contained 30-40% unrepaired breaks at 24 h. IGF-1R depletion induced significant reduction in DSB repair by HR, although the magnitude of the repair defect suggests additional contributory factors. Radiation-induced G2-M arrest was attenuated by IGF-1R depletion, potentially suppressing cell cycle-dependent processes required for HR. In contrast, IGF-1R depletion induced only minor radiosensitization in LNCaP cells, and did not influence repair. Cell cycle profiles were similar to DU145, so were unlikely to account for differences in repair responses.
CONCLUSIONS: These data indicate a role for IGF-1R in DSB repair, at least in part via HR, and support use of IGF-1R inhibitors with DNA damaging cancer treatments.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551565     DOI: 10.1016/j.radonc.2012.03.009

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  26 in total

Review 1.  Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Authors:  Helen King; Tamara Aleksic; Paul Haluska; Valentine M Macaulay
Journal:  Cancer Treat Rev       Date:  2014-08-04       Impact factor: 12.111

Review 2.  Peptide Hormone Regulation of DNA Damage Responses.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

3.  Growth Hormone Induces Colon DNA Damage Independent of IGF-1.

Authors:  Vera Chesnokova; Svetlana Zonis; Robert J Barrett; John P Gleeson; Shlomo Melmed
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

4.  Excess growth hormone suppresses DNA damage repair in epithelial cells.

Authors:  Vera Chesnokova; Svetlana Zonis; Robert Barrett; Hiraku Kameda; Kolja Wawrowsky; Anat Ben-Shlomo; Masaaki Yamamoto; John Gleeson; Catherine Bresee; Vera Gorbunova; Shlomo Melmed
Journal:  JCI Insight       Date:  2019-02-07

5.  Insulin-like growth factor-1 receptor regulates repair of ultraviolet B-induced DNA damage in human keratinocytes in vivo.

Authors:  Mathew M Loesch; Ann E Collier; David H Southern; Rachel E Ward; Sunil S Tholpady; Davina A Lewis; Jeffrey B Travers; Dan F Spandau
Journal:  Mol Oncol       Date:  2016-06-16       Impact factor: 6.603

6.  Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition.

Authors:  Kunal A Lodhia; Shan Gao; Tamara Aleksic; Fumiko Esashi; Valentine M Macaulay
Journal:  Int J Cancer       Date:  2014-11-25       Impact factor: 7.396

7.  Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.

Authors:  Oreekha Amin; Marie-Claude Beauchamp; Paul Abou Nader; Ido Laskov; Sanaa Iqbal; Charles-André Philip; Amber Yasmeen; Walter H Gotlieb
Journal:  BMC Cancer       Date:  2015-10-29       Impact factor: 4.430

8.  Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Authors:  V M Macaulay; M R Middleton; A S Protheroe; A Tolcher; V Dieras; C Sessa; R Bahleda; J-Y Blay; P LoRusso; D Mery-Mignard; J-C Soria
Journal:  Ann Oncol       Date:  2012-10-26       Impact factor: 32.976

Review 9.  Dual Characters of GH-IGF1 Signaling Pathways in Radiotherapy and Post-radiotherapy Repair of Cancers.

Authors:  Yunyun Cheng; Wanqiao Li; Ruirui Gui; Chunli Wang; Jie Song; Zhaoguo Wang; Xue Wang; Yannan Shen; Zhicheng Wang; Linlin Hao
Journal:  Front Cell Dev Biol       Date:  2021-06-09

Review 10.  Radiosensitization in prostate cancer: mechanisms and targets.

Authors:  Diego A Palacios; Makito Miyake; Charles J Rosser
Journal:  BMC Urol       Date:  2013-01-26       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.